Application of 'omics technologies to biomarker discovery in inflammatory lung diseases

European Respiratory Journal

Volumn 42, Issue 3, 2013, Pages 802-825

  Wheelock, Craig E ^a   Goss, Victoria M ^b   Balgoma, David ^a   Nicholas, Ben ^b   Brandsma, Joost ^b   Skipp, Paul J ^b   Snowden, Stuart ^a   Burg, Dominic ^b   D'Amico, Arnaldo ^f   Horvath, Ildiko ^h   Chaiboonchoe, Amphun ⁱ   Ahmed, Hassan ⁱ   Ballereau, Stéphane ⁱ   Rossios, Christos ^c   Chung, Kian Fan ^c   Montuschi, Paolo ^g   Fowler, Stephen J ^d   Adcock, Ian M ^c   Postle, Anthony D ^b   Dahleń, Sven Erik ^a   Rowe, Anthony ^e   Sterk, Peter J ^j   Auffray, Charles ⁱ   Djukanović, Ratko ^b   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ UNIVERSITÉ LYON 1   (France)

^j UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; ICOSANOID; LEUKOTRIENE; LIPID; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; SPHINGOSINE 1 PHOSPHATE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DATA ANALYSIS; DISEASE MARKER; ELECTRONIC SENSOR; ELECTROSPRAY MASS SPECTROMETRY; EXPIRED AIR; FUNCTIONAL GENOMICS; HUMAN; INFORMATION PROCESSING; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; KNOWLEDGE MANAGEMENT; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLOMICS; MICROARRAY ANALYSIS; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; PROTEOMICS; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TRANSCRIPTOMICS;

BIOLOGICAL MARKERS; BREATH TESTS; BRONCHOALVEOLAR LAVAGE FLUID; CHROMATOGRAPHY, LIQUID; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; LIPID METABOLISM; LUNG DISEASES; MASS SPECTROMETRY; METABOLOMICS; PHENOTYPE; PNEUMONIA; PROTEOMICS; SPUTUM;

EID: 84878940718     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00078812     Document Type: Review

References (221)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181: 315-323.
3. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598-604.
4. Kitaguchi Y, Fujimoto K, Kubo K, et al. Characteristics of COPD phenotypes classified according to the findings of HRCT. Respir Med 2006; 100: 1742-1752. (Pubitemid 44283760)
5. The Global Initiative for Asthma. www.ginasthma.org/
6. The Global Initiative for Chronic Obstructive Lung Disease. www.goldcopd.org/
7. Szalma S, Koka V, Khasanova T, et al. Effective knowledge management in translational medicine. J Transl Med 2010; 8: 68.
8. Standards for the Reporting of Diagnostic Accuracy Studies. www.stard-statement.org Date last updated: April 22, 2008. Date last accessed: June 27, 2013.
9. Bossuyt PM, Reitsma J, Bruns DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138: W1-W12.
10. Griese M, Noss J, von Bredow C. Protein pattern of exhaled breath condensate and saliva. Proteomics 2002; 2: 690-696. (Pubitemid 34693569)
11. Breathomics Platform Netherlands. www.breathomics.nl Date last updated: June 20, 2013. Date last accessed: June 27, 2013.
12. Anderson LN, Anderson N. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Prot 2002; 1: 854-867.
13. Krug S, Kastenmüller G, Stückler F, et al. The dynamic range of the human metabolome revealed by challenges. FASEB J 2012; 26: 2607-2619.
14. Bray D. Molecular prodigality. Science 2003; 299: 1189-1190.
15. Joyce AR, Palsson BO. The model organism as a system: integrating 'omics' data sets. Nat Rev Mol Cell Biol 2006; 7: 198-210.
16. Wheelock CE, Wheelock AM, Kawashima S, et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol Biosyst 2009; 5: 588-602.
17. Fenn J, Mann M, Meng C, et al. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64-71. (Pubitemid 19252085)
18. Wilm M. Principles of electrospray ionization. Mol Cell Proteomics 2011; 10: M111.009407.
19. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007; 53: 852-858. (Pubitemid 46744240)
20. McLerran D, Grizzle WE, Feng Z, et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008; 54: 53-60. (Pubitemid 351182596)
21. Bowler RP, Canham ME, Ellison MC. Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry to identify patients with chronic obstructive pulmonary disease. COPD 2006; 3: 41-50. (Pubitemid 43869515)
22. Calvo FQ, Fillet M, de Seny D, et al. Biomarker discovery in asthma-related inflammation and remodeling. Proteomics 2009; 9: 2163-2170.
23. Gomes-Alves P, Imrie M, Gray RD, et al. SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease. Clin Biochem 2010; 43: 168-177.
24. Makarov A, Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J Chromatogr A 2010; 1217: 3938-3945.
25. Schuhmann K, Herzog R, Schwudke D, et al. Bottom-up shotgun lipidomics by higher energy collisional dissociation on LTQ Orbitrap mass spectrometers. Anal Chem 2011; 83: 5480-5487.
26. Masoodi M, Eiden M, Koulman A, et al. Comprehensive lipidomics analysis of bioactive lipids in complex regulatory networks. Anal Chem 2010; 82: 8176-8185.
27. Stoop MP, Coulier L, Rosenling T, et al. Quantitative proteomics and metabolomics analysis of normal human cerebrospinal fluid samples. Mol Cell Proteomics 2010; 9: 2063-2075.
28. Weber RJM, Southam AD, Sommer U, et al. Characterization of isotopic abundance measurements in high resolution FT-ICR and Orbitrap mass spectra for improved confidence of metabolite identification. Anal Chem 2011; 83: 3737-3743.
29. Broadbelt KG, Rivera KD, Paterson DS, et al. Brainstem deficiency of the 14-3-3 regulator of serotonin synthesis: a proteomics analysis in the sudden infant death syndrome. Mol Cell Proteomics 2012; 11: M111.009530.
30. Hart P, Francese S, Claude E, et al. MALDI-MS imaging of lipids in ex vivo human skin. Anal Bioanal Chem 2011; 401: 115-125.
31. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom 2011; 46: 298-312.
32. Han X, Gross RW. Shotgun lipidomics: multidimensional MS analysis of cellular lipidomes. Expert Rev Proteomics 2005; 2: 253-264. (Pubitemid 40529863)
33. Soga T, Ohashi Y, Ueno Y, et al. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2: 488-494. (Pubitemid 37376843)
34. Čáp P, Chládek J, Pehal F, et al. Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients. Thorax 2004; 59: 465-470. (Pubitemid 38797517)
35. Carraro S, Rezzi S, Reniero F, et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2007; 175: 986-990. (Pubitemid 46741749)
36. Washburn MP, Wolters D, Yates JR. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242-247. (Pubitemid 32220565)
37. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137: 1410-1416.
38. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol 2011; 9: 34.
39. Imbeaud S, Auffray C. 'The 39 steps' in gene expression profiling: critical issues and proposed best practices for microarray experiments. Drug Discov Today 2005; 10: 1175-1182. (Pubitemid 41327774)
40. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009; 1: 2.
41. Brazma A, Hingamp P, Quackenbush J, et al. Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat Genet 2001; 29: 365-371. (Pubitemid 34326681)
42. Brazma A. Minimum Information About a Microarray Experiment (MIAME) - successes, failures, challenges. Scientific World Journal 2009; 9: 420-423.
43. Hurd PJ, Nelson CJ. Advantages of next-generation sequencing versus the microarray in epigenetic research. Brief Funct Genomic Proteomic 2009; 8: 174-183.
44. Pickrell JK, Marioni JC, Pai AA, et al. Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 2010; 464: 768-772.
45. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10: 57-63.
46. Mortazavi A, Williams BA, McCue K, et al. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621-628. (Pubitemid 351911867)
47. Raz T, Kapranov P, Lipson D, et al. Protocol dependence of sequencing-based gene expression measurements. PLoS One 2011; 6: e19287.
48. Ask K, Eickelberg O, Gauldie J, et al. Have advanced research technologies made real impact on respiratory medicine? Respirology 2010; 15: 876-880.
49. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-15863. (Pubitemid 350035389)
50. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
51. Choy DF, Modrek B, Abbas AR, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol 2011; 186: 1861-1869.
52. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
53. + T-cells reflects heterogeneity in infant wheezing phenotypes. Eur Respir J 2008; 32: 1203-1212.
54. Tsitsiou E, Williams AE, Moschos SA, et al. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J Allergy Clin Immunol 2012; 129: 95-103.
55. Al-Garawi A, Husain M, Ilieva D, et al. Shifting of immune responsiveness to house dust mite by influenza A infection: genomic insights. J Immunol 2012; 188: 832-843.
56. Tilley AE, O'Connor TP, Hackett NR, et al. Biologic phenotyping of the human small airway epithelial response to cigarette smoking. PLoS One 2011; 6: e22798.
57. Heguy A, O'Connor T, Luettich K, et al. Gene expression profiling of human alveolar macrophages of phenotypically normal smokers and nonsmokers reveals a previously unrecognized subset of genes modulated by cigarette smoking. J Mol Med 2006; 84: 318-328.
58. Harvey BG, Heguy A, Leopold P, et al. Modification of gene expression of the small airway epithelium in response to cigarette smoking. J Mol Med 2007; 85: 39-53. (Pubitemid 46020941)
59. Pierrou S, Broberg P, O'Donnell RA, et al. Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 577-586. (Pubitemid 46438942)
60. Beane J, Vick J, Schembri F, et al. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev Res (Phila) 2011; 4: 803-817.
61. Steiling K, Kadar AY, Bergerat A, et al. Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers. PLoS One 2009; 4: e5043.
62. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng 2009; 11: 49-79.
63. Palmblad M, Tiss A, Cramer R. Mass spectrometry in clinical proteomics - from the present to the future. Proteomics Clin Appl 2009; 3: 6-17.
64. Nicholas B, Skipp P, Mould R, et al. Shotgun proteomic analysis of human-induced sputum. Proteomics 2006; 6: 4390-4401. (Pubitemid 44277040)
65. Louten J, Mattson JD, Malinao MC, et al. Biomarkers of disease and treatment in murine and cynomolgus models of chronic asthma. Biomark Insights 2012; 7: 87-104.
66. Bozinovski S, Hutchinson A, Thompson M, et al. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 269-278. (Pubitemid 351198369)
67. Merkel D, Rist W, Seither P, et al. Proteomic study of human bronchoalveolar lavage fluids from smokers with chronic obstructive pulmonary disease by combining surface-enhanced laser desorption/ionization-mass spectrometry profiling with mass spectrometric protein identification. Proteomics 2005; 5: 2972-2980. (Pubitemid 41059773)
68. Nicholas BL, Skipp P, Barton S, et al. Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 1049-1060.
69. Ohlmeier S, Mazur W, Linja-Aho A, et al. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to- moderate COPD. J Proteome Res 2012; 11: 599-608.
70. Kohler M, Sandberg A, Kjellqvist S, et al. Gender differences in the bronchoalveolar lavage cell proteome of patients with COPD. J Allergy Clin Immunol 2012 [In press DOI: 10.106/j.jaci.2012.09.024].
71. Haynes PA, Yates JR. Proteome profiling - pitfalls and progress. Yeast 2000; 17: 81-87.
72. Bortner JD, Richie JP, Das A, et al. Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITIHC3 and VDBP by cigarette smoking. J Proteome Res 2010; 10: 1151-1159.
73. O'Neil SE, Lundbäck B, Lötvall J. Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J Proteomics 2011; 75: 192-201.
74. Silva JC, Gorenstein MV, Li GZ, et al. Absolute quantification of proteins by LCMSE: a virtue of parallel MS acquisition. Mol Cell Proteomics 2006; 5: 144-156. (Pubitemid 43169347)
75. Gharib SA, Nguyen EV, Lai Y, et al. Induced sputum proteome in healthy subjects and asthmatic patients. J Allergy Clin Immunol 2011; 128: 1176-1184.
76. Bai Y, Galetskiy D, Damoc E, et al. High resolution mass spectrometric alveolar proteomics: identification of surfactant protein SP-A and SP-D modifications in proteinosis and cystic fibrosis patients. Proteomics 2004; 4: 2300-2309. (Pubitemid 39025330)
77. Fu Q, Schoenhoff FS, Savage WJ, et al. Multiplex assays for biomarker research and clinical application: Translational science coming of age. Proteomics Clin Appl 2010; 4: 271-284.
78. Schlatzer DM, Dazard JE, Ewing RM, et al. Human biomarker discovery and predictive models for disease progression for idiopathic pneumonia syndrome following allogeneic stem cell transplantation. Mol Cell Proteomics 2012; 11: M111.015479.
79. Freire SLS, Yang H, Wheeler AR. A practical interface for microfluidics and nanoelectrospray mass spectrometry. Electrophoresis 2008; 29: 1836-1843. (Pubitemid 351663879)
80. Lundström SL, Balgoma D, Wheelock ÅM, et al. Lipid mediator profiling in pulmonary disease. Curr Pharm Biotechnol 2011; 12: 1026-1052.
81. Wright SM, Hockey PM, Enhorning G, et al. Altered airway surfactant phospholipid composition and reduced lung function in asthma. J Appl Physiol 2000; 89: 1283-1292.
82. Heeley EL, Hohlfeld JM, Krug N, et al. Phospholipid molecular species of bronchoalveolar lavage fluid after local allergen challenge in asthma. Am J Physiol Lung Cell Mol Physiol 2000; 278: L305-L311. (Pubitemid 30131215)
83. Erpenbeck VJ, Krug N, Hohlfeld JM. Therapeutic use of surfactant components in allergic asthma. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 217-224.
84. Babu KS, Woodcock DA, Smith SE, et al. Inhaled synthetic surfactant abolishes the early allergen-induced response in asthma. Eur Respir J 2003; 21: 1046-1049. (Pubitemid 36675624)
85. Arbibe L, Koumanov K, Vial D, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J Clin Invest 1998; 102: 1152-1160. (Pubitemid 28436275)
86. Furue S, Mikawa K, Nishina K, et al. Therapeutic time-window of a group IIA phospholipase A2 inhibitor in rabbit acute lung injury: correlation with lung surfactant protection. Crit Care Med 2001; 29: 719-727. (Pubitemid 32299707)
87. Hite RD, Seeds MC, Bowton DL, et al. Surfactant phospholipid changes after antigen challenge: a role for phosphatidylglycerol in dysfunction. Am J Physiol Lung Cell Mol Physiol 2005; 288: L610-L617. (Pubitemid 40404127)
88. Numata M, Chu HW, Dakhama A, et al. Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection. Proc Natl Acad Sci USA 2010; 107: 320-325.
89. Almstrand AC, Josefson M, Bredberg A, et al. TOF-SIMS analysis of exhaled particles from patients with asthma and healthy controls. Eur Respir J 2012; 39: 59-66.
90. Kim RH, Takabe K, Milstien S, et al. Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 2009; 1791: 692-696.
91. Ammit AJ, Hastie AT, Edsall LC, et al. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. FASEB J 2001; 15: 1212-1214.
92. Ryan JJ, Spiegel S. The role of sphingosine-1-phosphate and its receptors in asthma. Drug News Perspect 2008; 21: 89-96. (Pubitemid 351628233)
93. Breslow DK, Collins SR, Bodenmiller B, et al. Orm family proteins mediate sphingolipid homeostasis. Nature 2010; 463: 1048-1053.
94. Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470-473. (Pubitemid 47123521)
95. Clarke DL, Dakshinamurti S, Larsson AK, et al. Lipid metabolites as regulators of airway smooth muscle function. Pulm Pharmacol Ther 2009; 22: 426-435.
96. Toews ML, Ediger TL, Romberger DJ, et al. Lysophosphatidic acid in airway function and disease. Biochim Biophys Acta 2002; 1582: 240-250. (Pubitemid 34634135)
97. Zhao Y, Tong J, He D, et al. Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. Respir Res 2009; 10: 114.
98. Lundström SL, Levänen B, Nording M, et al. Asthmatics exhibit altered oxylipin profiles compared to healthy individuals after subway air exposure. PLoS One 2011; 6: e23864.
99. Lundström SL, Yang J, Källberg HJ, et al. Allergic asthmatics show divergent lipid mediator profiles from healthy controls both at baseline and following birch pollen provocation. PLoS One 2012; 7: e33780.
100. Kupczyk M, Lundstrom S, Dahlen B, et al. Lipid mediators in severe asthma. In: Chung KF, Bel EH, Wenzel SE, eds. Difficult-to-treat Severe Asthma. Eur Respir Monogr 2011; 51: 218-235.
101. 2) receptor agonists as therapeutic agents for the treatment of asthma. Sci STKE 2005; 2005: pe47.
102. Raud J, Dahlén SE, Sydbom A, et al. Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release. Proc Natl Acad Sci USA 1988; 85: 2315-2319. (Pubitemid 24315882)
103. Dahlén SE, Kumlin M. Monitoring mast cell activation by prostaglandin D2 in vivo. Thorax 2004; 59: 453-455. (Pubitemid 38797513)
104. Bochenek G, Nagraba K, Niżankowska E, et al. A controlled study of 9α,11β-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol 2003; 111: 743-749. (Pubitemid 36470243)
105. Bochenek G, Niżankowska E, Gielicz A, et al. Plasma 9α,11β-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004; 59: 459-464. (Pubitemid 38797516)
106. Daham K, Song WL, Lawson JA, et al. Effects of celecoxib on major prostaglandins in asthma. Clin Exp Allergy 2011; 41: 36-45.
107. Sladek K, Dworski R, Fitzgerald GA, et al. Allergen-stimulated release of thromboxane A2 and leukotriene E4 in humans: effect of indomethacin. Am Rev Respir Dis 1990; 141: 1441-1445. (Pubitemid 20201339)
108. Kumlin M, Dahlén B, Björck T, et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96-103.
109. Dixon RAF, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature 1990; 343: 282-284.
110. Dahlen SE, Hedqvist P, Hammarstrom S, et al. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288: 484-486. (Pubitemid 11163960)
111. Hanna CJ, Bach MK, Pare PD, et al. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro. Nature 1981; 290: 343-344. (Pubitemid 11107251)
112. Weiss J, Drazen J, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216: 196-198. (Pubitemid 12089845)
113. Serhan CN, Samuelsson B. Lipoxins: a new series of eicosanoids (biosynthesis, stereochemistry, and biological activities). Adv Expl Med Biol 1988; 229: 1-14.
114. Levy BD, De Sanctis GT, Devchand PR, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat Med 2002; 8: 1018-1023. (Pubitemid 35033707)
115. Bonnans C, Vachier I, Chavis C, et al. Lipoxins are potential endogenous antiinflammatory mediators in asthma. Am J Respir Crit Care Med 2002; 165: 1531-1535. (Pubitemid 34606669)
116. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011; 111: 5866-5898.
117. Kumlin M, Hamberg M, Granström E, et al. 15(S)- Hydroxyeicosatetraenoic acid is the major arachidonic acid metabolite in human bronchi: association with airway epithelium. Arch Biochem Biophys 1990; 282: 254-262. (Pubitemid 20384226)
118. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition. Clin Exp Allergy 2002; 32: 1558-1565. (Pubitemid 35370530)
119. Liu C, Xu D, Liu L, et al. 15-Lipoxygenase-1 induces expression and release of chemokines in cultured human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 2009; 297: L196-L203.
120. Feltenmark S, Gautam N, Brunnström Å, et al. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. Proc Natl Acad Sci USA 2008; 105: 680-685. (Pubitemid 351171768)
121. Ono E, Mita H, Taniguchi M, et al. Concentration of 14,15-leukotriene C4 (eoxin C4) in bronchoalveolar lavage fluid. Clin Exp Allergy 2009; 39: 1348-1352.
122. Sachs-Olsen C, Sanak M, Lang AM, et al. Eoxins: a new inflammatory pathway in childhood asthma. J Allergy Clin Immunol 2010; 126: 859-867.
123. Montuschi P, Currò D, Ragazzoni E, et al. Anaphylaxis increases 8-iso-prostaglandin F2α release from guinea-pig lung in vitro. Eur J Pharmacol 1999; 365: 59-64. (Pubitemid 29070720)
124. Dworski R, Murray JJ, Roberts LJ 2nd, et al. Allergen-induced synthesis of F2-isoprostanes in atopic asthmatics. Am J Respir Crit Care Med 1999; 160: 1947-1951.
125. Cracowski JL, Cracowski C, Bessard G, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 1038-1042. (Pubitemid 32971655)
126. Wood LG, Gibson PG, Garg ML. Biomarkers of lipid peroxidation, airway inflammation and asthma. Euro Respir J 2003; 21: 177-186. (Pubitemid 36150317)
127. Morrow JD, Hill KE, Burk RF, et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387. (Pubitemid 120030630)
128. Higashi A, Higashi N, Tsuburai T, et al. Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis. Eur Respir J 2005; 26: 1069-1073. (Pubitemid 41829938)
129. Thomas MC, Mitchell TW, Harman DG, et al. Ozone-induced dissociation: elucidation of double bond position within mass-selected lipid ions. Anal Chem 2007; 80: 303-311. (Pubitemid 351448435)
130. Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp Funct Genom 2001; 2: 155-168. (Pubitemid 32590962)
131. Oliver SG, Winson MK, Kell DB, et al. Systematic functional analysis of the yeast genome. Trends Biotechnol 1998; 16: 373-378. (Pubitemid 28410425)
132. Snowden S, Dahlén SE, Wheelock CE. Application of metabolomics approaches to the study of respiratory diseases. Bioanalysis 2012; 4: 2265-2290.
133. Saude EJ, Skappak CD, Regush S, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol 2011; 127: 757-764.
134. Mattarucchi E, Baraldi E, Guillou C. Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr 2012; 26: 89-94.
135. Ubhi BK, Riley JH, Shaw PA, et al. Metabolic profiling detects biomarkers of protein degradation in COPD patients. Eur Respir J 2012; 40: 345-355.
136. Paige M, Burdick MD, Kim S, et al. Pilot analysis of the plasma metabolite profiles associated with emphysematous chronic obstructive pulmonary disease phenotype. Biochem Biophys Res Commun 2011; 413: 588-593.
137. Montuschi P, Paris D, Melck D, et al. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax 2012; 67: 222-228.
138. Sonntag D, Scandurra F, Friedrich T, et al. Targeted metabolomics for bioprocessing. BMC Proc 2011; 5: Suppl. 8, P27.
139. Pauling L, Robinson A, Teranishi RR, et al. Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography. Proc Natl Acad Sci USA 1971; 68: 2374-2376.
140. Horvath I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005; 26: 523-548. (Pubitemid 41264218)
141. Phillips M. Method for the collection and assay of volatile organic compounds in breath. Anal Biochem 1997; 247: 272-278. (Pubitemid 27200161)
142. D'Amico A, Di Natale C, Paolesse R, et al. Olfactory systems for medical applications. Sensor Actuat B: Chemical 2008; 130: 458-465. (Pubitemid 351380438)
143. Röck F, Barsan N, Weimar U. Electronic nose: current status and future trends. Chem Rev 2008; 108: 705-713.
144. Broadhurst D, Kell D. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2006; 2: 171-196. (Pubitemid 46099798)
145. Sung J, Wang Y, Chandrasekaran S, et al. Molecular signatures from omics data: from chaos to consensus. Biotechnol J 2012; 7: 946-957.
146. Scott SM, James D, Ali Z. Data analysis for electronic nose systems. Microchim Acta 2006; 156: 183-207.
147. Horváth I, Lázár Z, Gyulai N, et al. Exhaled biomarkers in lung cancer. Eur Respir J 2009; 34: 261-275.
148. de Laurentiis G, Paris D, Melck D, et al. Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy. Eur Respir J 2008; 32: 1175-1183.
149. Phillips M, Altorki N, Austin JH, et al. Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008; 393: 76-84.
150. Dallinga JW, Robroeks CM, van Berkel JJ, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy 2010; 40: 68-76.
151. Montuschi P, Santonico M, Mondino C, et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010; 137: 790-796.
152. Bennett L, Ciaffoni L, Denzer W, et al. A chemometric study on human breath mass spectra for biomarker identification in cystic fibrosis. J Breath Res 2009; 3: 046002.
153. Van Berkel JJ, Dallinga JW, Möller GM, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 2010; 104: 557-563.
154. Ibrahim B, Basanta M, Cadden P, et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 2011; 66: 804-809.
155. Fens N, de Nijs SB, Peters S, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J 2011; 38: 1301-1309.
156. Dragonieri S, Schot R, Mertens BJ, et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120: 856-862. (Pubitemid 47542280)
157. Fens N, Zwinderman AH, van der Schee MP, et al. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med 2009; 180: 1076-1082.
158. Fens N, Roldaan AC, van der Schee MP, et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy 2011; 41: 1371-1378.
159. Lazar Z, Fens N, van der Maten J, et al. Electronic nose breathprints are independent of acute changes in airway caliber in asthma. Sensors (Basel) 2010; 10: 9127-9138.
160. Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer 2010; 103: 542-551.
161. Shaham O, Carmel L, Harel D. On mappings between electronic noses. Sensor Actuat B: Chemical 2005; 106: 76-82.
162. Robroeks CM, Rijkers GT, Jöbsis Q, et al. Increased cytokines, chemokines and soluble adhesion molecules in exhaled breath condensate of asthmatic children. Clin Exp Allergy 2010; 40: 77-84.
163. Motta A, Paris D, Melck D, et al. Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects. Eur Respir J 2012; 39: 498-500.
164. Auffray C, Imbeaud S, Roux-Rouquié M, et al. From functional genomics to systems biology: concepts and practices. C R Biol 2003; 326: 879-892. (Pubitemid 38016443)
165. Kohl P, Noble D. Systems biology and the virtual physiological human. Mol Syst Biol 2009; 5: 292.
166. Westerhoff H, Kolodkin A, Conradie R, et al. Systems biology towards life in silico: mathematics of the control of living cells. J Math Biol 2009; 58: 7-34.
167. Schmelzer K, Fahy E, Subramaniam S, et al. The lipid maps initiative in lipidomics. Method Enzymol 2007; 432: 171-183.
168. Dupuy A, Simon RM. Critical review of published microarray studies for
169. Diez D, Wheelock AM, Goto S, et al. The use of network analyses for elucidating mechanisms in cardiovascular disease. Mol Biosyst 2010; 6: 289-304.
170. Ghosh S, Matsuoka Y, Asai Y, et al. Software for systems biology: from tools to integrated platforms. Nat Rev Genet 2011; 12: 821-832.
171. IPA. www.ingenuity.com/products/ipa
172. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504. (Pubitemid 37428274)
173. Margolin AA, Nemenman I, Basso K, et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006; 7: Suppl. 1, S7.
174. Diez D, Goto S, Fahy JV, et al. Network analysis identifies a putative role for the PPAR and type 1 interferon pathways in glucocorticoid actions in asthmatics. BMC Med Genomics 2012; 5: 27.
175. Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010; 38: D355-D360.
176. Novere NL, Hucka M, Mi H, et al. The systems biology graphical notation. Nat Biotech 2009; 27: 735-741.
177. Funahashi A, Matsuoka Y, Jouraku A, et al. CellDesigner 3.5: a versatile modeling tool for biochemical networks. Proc IEEE 2008; 96: 1254-1265.
178. Smoot ME, Ono K, Ruscheinski J, et al. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011; 27: 431-432.
179. Krallinger M, Valencia A, Hirschman L. Linking genes to literature: text mining, information extraction, and retrieval applications for biology. Genome Biol 2008; 9: Suppl. 2, S8.
180. Tsuruoka Y, Miwa M, Hamamoto K, et al. Discovering and visualizing indirect associations between biomedical concepts. Bioinformatics 2011; 27: i111-i119.
181. Kelder T, van Iersel MP, Hanspers K, et al. WikiPathways: building research communities on biological pathways. Nucleic Acids Res 2012; 40: D1301-D1307.
182. PubMed. National Center for Biotechnology Information. www.ncbi.nlm.nih.gov/pubmed
183. Bader GD, Betel D, Hogue CW. BIND: the Biomolecular Interaction Network Database. Nucleic Acids Res 2003; 31: 248-50. (Pubitemid 36150376)
184. Matthews L, Gopinath G, Gillespie M, et al. Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009; 37: D619-D622.
185. KEGG: Kyoto Encyclopedia of Genes and Genomes. www.genome.jp/kegg/
186. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29. (Pubitemid 30257031)
187. Courtot M, Juty N, Knüpfer C, et al. Controlled vocabularies and semantics in systems biology. Mol Syst Biol 2011; 7: 543.
188. Galaxy. http://galaxyproject.org Date last updated: November 6, 2012. Date last accessed: July 1, 2013.
189. Berthold MR, Cebron N, Dill F, et al. KNIME - the Konstanz information miner: version 2.0 and beyond. SIGKDD Explorations 2009; 11: 26-31.
190. Flicek P, Amode MR, Barrell D, et al. Ensembl 2012. Nucleic Acids Res 2012; 40: D84-D90.
191. Kuhn RM, Haussler D, Kent WJ. The UCSC genome browser and associated tools. Briefing Bioinform 2012 [In press DOI: 10.1093/bib/bbs038].
192. tranSMART. www.transmartfoundation.org Date last updated: June 27, 2013. Date last accessed: June 27, 2013.
193. Perakslis ED, Van Dam J, Szalma S. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development. Clin Pharmacol Ther 2010; 87: 614-616.
194. Informatics for Integrating Biology and the Bedside. A National Center for Biomedical Computing. www.i2b2.org/ Date last accessed: June 27, 2013.
195. The R Project for Statistical Computing. www.r-project.org Date last updated: May 16, 2013. Date last accessed: June 27, 2013.
196. Maier D, Kalus W, Wolff M, et al. Knowledge management for systems biology a general and visually driven framework applied to translational medicine. BMC Syst Biol 2011; 5: 38.
197. Figueroa RL, Zeng-Treitler Q, Kandula S, et al. Predicting sample size required for classification performance. BMC Med Inform Decis Mak 2012; 12: 8.
198. Burton PR, Hansell AL, Fortier I, et al. Size matters: just how big is BIG? Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol 2009; 38: 263-273.
199. Jung SH, Young SS. Power and sample size calculation for microarray studies. J Biopharm Stat 2012; 22: 30-42.
200. Liu P, Hwang JT. Quick calculation for sample size while controlling false discovery rate with application to microarray analysis. Bioinformatics 2007; 23: 739-746. (Pubitemid 46554726)
201. Matsui S, Noma H. Estimating effect sizes of differentially expressed genes for power and sample-size assessments in microarray experiments. Biometrics 2011; 67: 1225-1235.
202. Page GP, Edwards JW, Gadbury GL, et al. The PowerAtlas: a power and sample size atlas for microarray experimental design and research. BMC Bioinformatics 2006; 7: 84.
203. Kato BS, Nicholson G, Neiman M, et al. Variance decomposition of protein profiles from antibody arrays using a longitudinal twin model. Proteome Sci 2011; 9: 73.
204. Nicholson G, Rantalainen M, Maher AD, et al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol Syst Biol 2011; 7: 525.
205. Gehlenborg N, O'Donoghue S, Baliga NS, et al. Visualization of omics data for systems biology. Nat Methods 2010; 7: Suppl. 3, S56-S68.
206. Chen R, Mias George I, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012; 148: 1293-307.
207. Turan N, Kalko S, Stincone A, et al. A systems biology approach identifies molecular networks defining skeletal muscle abnormalities in chronic obstructive pulmonary disease. PLoS Comput Biol 2011; 7: e1002129.
208. Lusis AJ. A thematic review series: systems biology approaches to metabolic and cardiovascular disorders. J Lipid Res 2006; 47: 1887-1890. (Pubitemid 44401976)
209. Young D, Stark J, Kirschner D. Systems biology of persistent infection: tuberculosis as a case study. Nat Rev Micro 2008; 6: 520-528. (Pubitemid 351850976)
210. Hwang D, Lee IY, Yoo H, et al. A systems approach to prion disease. Mol Syst Biol 2009; 5: 252.
211. Casado-Vela J, Cebrián A, Gómez del Pulgar MT, et al. Approaches for the study of cancer: towards the integration of genomics, proteomics and metabolomics. Clin Transl Oncol 2011; 13: 617-628.
212. Chuang HY, Lee E, Liu YT, et al. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007; 3: 140.
213. He JC, Chuang PY, Ma'Ayan A, et al. Systems biology of kidney diseases. Kidney Int 2012; 81: 22-39.
214. Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J 2012; 7: 992-1001.
215. U-BIOPRED. www.ubiopred.european-lung-foundation.org Date last updated: June 14, 2013. Date last accessed: June 27, 2013.
216. AirPROM. www.airprom.european-lung-foundation.org Date last updated: May 8, 2013. Date last accessed: June 27, 2013.
217. MeDALL. Mechanisms of the Development of Allergy. http://medall-fp7.eu/ Last updated: April 2013. Date last accessed: June 27, 2013.
218. Bousquet J, Anto J, Auffray C, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy 2011; 66: 596-604.
219. Brightling CE, Gupta S, Gonem S, et al. Lung damage and airway remodelling in severe asthma. Clin Exp Allergy 2012; 42: 638-649.
220. Synergy-COPD project. www.synergy-copd.eu Date last updated: March 12, 2013. Date last accessed: June 27, 2013.
221. Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, The National Academies Press, 2012.